Rutherford Health - Result of AGM London Stock Exchange
RNS Number : 8627W
Rutherford Health PLC
21 August 2020

Rutherford Health Plc


Results of Annual General Meeting


London, UK, 21 August 2020: Rutherford Health plc (the "Company" or "Group" or "Rutherford Health") announces that at its annual general meeting ("AGM") held earlier today, shareholders passed resolutions 1,5,6,7, and 9.


Shareholders did not pass resolutions 2, 3 and 4, being the resolutions to re-elect as directors Timothy Irish, Andrew Bennett and Diana Dyer-Bartlett, who therefore retire from the board. The Company thanks them for their service.


Resolution 8, which would have enabled the Company to make off-market purchases of its own shares, was also not passed by shareholders.


Holding in Company and Total Voting Rights


As a result of the passing of resolution 9, the Company's articles of association ("Articles") have been changed with the result that LF Equity Income Fund is no longer restricted to 19.50% of the Company's voting rights.


As announced on 11 March 2020, LF Equity Income Fund holds 57,027,018 Rutherford ordinary shares of £0.001 each ("Ordinary Shares"), representing 28.81% of the Company's issued share capital. As a result of the amendment to the Articles, LF Equity Income Fund now also holds 28.81%  of the Company's voting rights.


For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), as a result of the changes to the Articles, Rutherford has 197,973,238 Ordinary Shares in issue with voting rights attached. Rutherford holds no shares in treasury. This figure of  197,973,238 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the DTRs.


A copy of the notice of AGM and the amended Articles may be found on the Company's website,



The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.


The directors of the Company accept responsibility for the content of this announcement.





Rutherford Health plc

Michael Moran, Chief Executive Officer

Tel: +44 (0) 16 3381 0661



Grant Thornton (Corporate Adviser)

Colin Aaronson / Niall McDonald

Tel: +44 (0) 20 7383 5100



Media House International   

07788 414 856 or 0207 710 0020

Ramsay Smith



About Rutherford Health plc

Rutherford Health plc is at the vanguard of advancing cancer care. Developing and building a network of oncology centres across the UK known as the Rutherford Cancer Centres, offering a comprehensive range of cancer treatments to patients.


The first centre in Newport, South Wales, was the first in the UK to offer high energy proton therapy. In addition, each centre also offers radiotherapy, chemotherapy, immunotherapy, diagnostic imaging and supportive care services.


As well as the Rutherford Cancer Centre North West, Rutherford Health plc (formerly known as Proton Partners International Limited) has opened three further centres - the Rutherford Cancer Centre South Wales in Newport, Rutherford Cancer Centre North East in Northumberland and the Rutherford Cancer Centre Thames Valley in Reading, with proton therapy available in those three centres.


Rutherford Health plc has partnered with world-leading healthcare technology providers to equip each centre with the very latest and innovative technology, including IBA, Philips and Elekta.


Rutherford Health plc was founded in 2015 by Mike Moran MBE and UK and international cancer experts, including Professor Edward Karol Sikora, former head of the World Health Organisation's cancer programme.






This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit